Signaling through estrogen receptors modulates telomerase activity in human prostate cancer

Simona Nanni, Michela Narducci, Linda Della Pietra, Fabiola Moretti, Annalisa Grasselli, Piero De Carli, Ada Sacchi, Alfredo Pontecorvi, Antonella Farsetti

Research output: Contribution to journalArticlepeer-review

Abstract

Sex steroid hormone receptors play a central role in all stages of prostate cancer. Here, we tested whether estrogen receptor (ER) signaling contributes to telomerase activation, an early event in prostate tumorigenesis. Following 17β-estradiol (E2) treatment, both mRNA encoding the catalytic subunit of human telomerase (hTERT) and telomerase activity were promptly induced in human prostate normal epithelial cells, fresh explants from benign prostate hyperplasia, and prostate cancer explants and cell lines. Reporter expression studies and in vivo chromatin immunoprecipitation assays revealed E2-dependent hTERT promoter induction and showed that both ERα and ERβ bound this sequence. Crucially, addition of the anti-estrogen 4-hydroxytamoxifen caused a differential recruitment in vivo of ERα and ERβ onto the hTERTpromoter and inhibited telomerase activity. Treatment with the aromatase inhibitor letrozole, which prevented testosterone-mediated interaction between ER and the hTERT estrogen response element, resulted in a negative regulation of telomerase activity. Thus, intracellular conversion of androgens to estrogens may contribute to the etiopathogenesis of prostate cancer. Given the present evidence for direct control of hTERT gene expression and telomerase activity in the prostate by the ER, we suggest that this transcriptional regulator represents a possible therapeutic target in prostate cancer.

Original languageEnglish
Pages (from-to)219-227
Number of pages9
JournalJournal of Clinical Investigation
Volume110
Issue number2
DOIs
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Signaling through estrogen receptors modulates telomerase activity in human prostate cancer'. Together they form a unique fingerprint.

Cite this